Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $13.6 million.
- Spero Therapeutics' Total Current Liabilities fell 7219.94% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 7219.94%. This contributed to the annual value of $49.1 million for FY2024, which is 3208.62% up from last year.
- Per Spero Therapeutics' latest filing, its Total Current Liabilities stood at $13.6 million for Q3 2025, which was down 7219.94% from $14.9 million recorded in Q2 2025.
- Spero Therapeutics' Total Current Liabilities' 5-year high stood at $69.2 million during Q1 2022, with a 5-year trough of $12.8 million in Q2 2021.
- Over the past 5 years, Spero Therapeutics' median Total Current Liabilities value was $21.6 million (recorded in 2022), while the average stood at $28.1 million.
- Per our database at Business Quant, Spero Therapeutics' Total Current Liabilities skyrocketed by 28956.82% in 2022 and then tumbled by 7219.94% in 2025.
- Quarter analysis of 5 years shows Spero Therapeutics' Total Current Liabilities stood at $18.7 million in 2021, then grew by 15.96% to $21.6 million in 2022, then skyrocketed by 71.62% to $37.2 million in 2023, then skyrocketed by 32.09% to $49.1 million in 2024, then crashed by 72.19% to $13.6 million in 2025.
- Its Total Current Liabilities stands at $13.6 million for Q3 2025, versus $14.9 million for Q2 2025 and $29.2 million for Q1 2025.